Jane Gross
Director/Board Member at ATYR PHARMA, INC.
Net worth: 9 570 $ as of 2024-04-29
Profile
Dr. Jane A.
Gross is an Independent Director at BriaCell Therapeutics Corp., an Independent Director at aTyr Pharma, Inc. and an Independent Director at BriaPro Therapeutics Corp.
She is on the Board of Directors at BriaCell Therapeutics Corp., aTyr Pharma, Inc., Washington Biotechnology & Biomedical Association and BriaPro Therapeutics Corp.
Dr. Gross was previously employed as a Chief Scientific Officer & Senior Vice President by Aptevo Therapeutics, Inc., a VP-Applied Research & Non-Clinical Development by Emergent BioSolutions, Inc., and a Vice President-Immunology Research by ZymoGenetics, Inc. She received her doctorate degree from the University of California, Berkeley.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ATYR PHARMA, INC.
0.01% | 2024-02-29 | 6,000 ( 0.01% ) | 9 570 $ | 2024-04-29 |
| 2023-12-19 | 0 ( -.--% ) | - $ | 2024-04-29 |
Jane Gross active positions
| Companies | Position | Start |
|---|---|---|
| ATYR PHARMA, INC. | Director/Board Member | 2019-06-27 |
| BRIACELL THERAPEUTICS CORP. | Director/Board Member | 2021-10-31 |
| Washington Biotechnology & Biomedical Association | Director/Board Member | - |
BriaPro Therapeutics Corp.
 BriaPro Therapeutics Corp. Pharmaceuticals: MajorHealth Technology BriaPro Therapeutics Corp. a clinical stage biotechnology company focuses on the development of BriaTILsRx™ and PKCd inhibitors for multiple indications including cancer. The company was founded on May 15, 2023 and is headquartered West Vancouver, Canada. | Director/Board Member | - |
Former positions of Jane Gross
| Companies | Position | End |
|---|---|---|
| APTEVO THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2021-09-13 |
| EMERGENT BIOSOLUTIONS INC. | Corporate Officer/Principal | 2016-07-31 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 2010-05-31 |
Training of Jane Gross
| University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| APTEVO THERAPEUTICS INC. | Health Technology |
| BRIACELL THERAPEUTICS CORP. | Health Technology |
| Private companies | 3 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
| Washington Biotechnology & Biomedical Association | |
BriaPro Therapeutics Corp.
BriaPro Therapeutics Corp. Pharmaceuticals: MajorHealth Technology BriaPro Therapeutics Corp. a clinical stage biotechnology company focuses on the development of BriaTILsRx™ and PKCd inhibitors for multiple indications including cancer. The company was founded on May 15, 2023 and is headquartered West Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Jane Gross
